<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03724994</url>
  </required_header>
  <id_info>
    <org_study_id>CHAMP</org_study_id>
    <nct_id>NCT03724994</nct_id>
  </id_info>
  <brief_title>Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer</brief_title>
  <acronym>CHAMP</acronym>
  <official_title>Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CHAMP (Chemotherapy, Host response And Molecular dynamics in Periampullary cancer) study
      is a prospective, single-arm observational study that started Sept 1 2018. Patients diagnosed
      with pancreatic or other periampullary adenocarcinoma undergoing adjuvant och palliative
      chemotherapy are invited to participate. The study will examine the tumors' molecular
      dynamics and how this may change over time and with treatment. Primary endpoint will be
      overall survival, secondary endpoints will be disease specific survival, time to progression,
      and quality of life. We estimate that 90 patients will be included in the study per year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CHAMP (Chemotherapy, Host response And Molecular dynamics in Periampullary cancer) study
      is a prospective, single-arm observational study that will start Sept 1 2018. All patients
      diagnosed with a histologically or cytologically confirmed diagnosis of pancreatic or other
      periampullary adenocarcinoma undergoing adjuvant or palliative chemotherapy treatment in the
      Department of Oncology, Skåne University Hospital, Malmö will be invited to participate. The
      estimated number of recruited patients is 90/year, 75 with pancreatic cancers. Of note tumour
      origin can seldom be firmly established in non-resectable cases, where only a fine needle
      aspiration or biopsy specimen is available before initiation of palliative chemotherapy. Main
      exclusion criteria are: 1. patients having another concomitant life-threatening disease and
      2. patients who are unable to receive chemotherapy will be informed about the study by their
      oncologist and a research nurse and, if they want to participate, will sign an informed
      consent form.

      The treatment regimen will follow national guidelines, and will not be affected by the study.
      Clinical and pathological data will be compiled at study entry. Radiological and clinical
      workup will be performed every three months. Primary endpoint will be overall survival,
      secondary endpoints will be disease specific survival, time to progression, and quality of
      life (EORTC-QLQ-PAN26). Serial sampling of blood during chemotherapy treatment will be
      performed by a dedicated research nurse along with the clinical routine sampling. Plasma and
      serum samples for analysis of ctDNA and cytokines, respectively, will be will be drawn before
      chemotherapy start (timepoint 0/T0), and prior to each additional course of chemotherapy
      (monthly e.g. gemcitabine based regimens; T1-5 or biweekly e.g. combination regimen
      FOLFIRINOX; T1-11), and after the last course of treatment (T6 or T12). Peripheral blood
      mononuclear cells (PBMC) will be isolated from buffy coat in plasma vials before start of
      chemotherapy (T0), before the second or third (T2/T3) (monthly or biweekly, respectively)
      course of chemotherapy, before the fourth or seventh (T4/T7) course of chemotherapy, and
      after the last course of treatment. A homepage is under construction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>5 years</time_frame>
    <description>months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease specific survival</measure>
    <time_frame>5 years</time_frame>
    <description>months</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Periampullary Adenocarcinoma</condition>
  <condition>Periampullary Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Study cohort</arm_group_label>
    <description>All patients with periampullary adenocarcinoma or pancreatic cancer receiving palliative or adjuvant chemotherapy (e.g. Gemcitabine, Folfirinox, etc.) in the Department of Oncology, Skåne University hospital, Malmö</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Adjuvant or palliative chemotherapy according to national guidelines</description>
    <arm_group_label>Study cohort</arm_group_label>
    <other_name>Folfirinox</other_name>
    <other_name>Gemcitabine - nab-paclitaxel</other_name>
    <other_name>Fluorouracil</other_name>
    <other_name>FLOX</other_name>
    <other_name>5-FU</other_name>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma samples (for circulating tumor DNA) and serum samples (for cytokines) Tumor cytology
      and/or tumor biopsy for biomarkers and mutations.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with a histologically or cytologically confirmed diagnosis of pancreatic
        or other periampullary adenocarcinoma undergoing adjuvant or palliative chemotherapy
        treatment in the Department of Oncology, Skåne University Hospital, Malmö will be invited
        to participate.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients diagnosed with a histologically or cytologically confirmed diagnosis of pancreatic
        or other periampullary adenocarcinoma undergoing adjuvant or palliative chemotherapy
        treatment in the Department of Oncology, Skåne University Hospital, Malmö.

        Exclusion Criteria:

          1. patients having another concomitant life-threatening disease and

          2. patients who are unable to receive chemotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Karin Jirström, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Lunds University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karin Leandersson, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Lunds University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margareta Heby, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Lunds University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sofie Olsson Hau, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Lunds University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karin Jirström, Professor</last_name>
    <phone>+46 46 2220829</phone>
    <email>karin.jirstrom@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maragreta Heby, MD</last_name>
    <phone>+46 40 337892</phone>
    <email>margareta.heby@med.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Oncology, Skåne University Hospital</name>
      <address>
        <city>Malmö</city>
        <state>Skåne</state>
        <zip>214 28</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margareta Heby, MD</last_name>
      <phone>+46 40 337892</phone>
      <email>margareta.heby@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>Karin Jirström, Professor</last_name>
      <phone>+46 2220829</phone>
      <email>karin.jirstrom@med.lu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Heby M, Lundgren S, Nodin B, Elebro J, Eberhard J, Jirström K. Relationship between mismatch repair immunophenotype and long-term survival in patients with resected periampullary adenocarcinoma. J Transl Med. 2018 Mar 14;16(1):66. doi: 10.1186/s12967-018-1444-4.</citation>
    <PMID>29540182</PMID>
  </reference>
  <reference>
    <citation>Karnevi E, Dror LB, Mardinoglu A, Elebro J, Heby M, Olofsson SE, Nodin B, Eberhard J, Gallagher W, Uhlén M, Jirström K. Translational study reveals a two-faced role of RBM3 in pancreatic cancer and suggests its potential value as a biomarker for improved patient stratification. Oncotarget. 2017 Dec 15;9(5):6188-6200. doi: 10.18632/oncotarget.23486. eCollection 2018 Jan 19.</citation>
    <PMID>29464064</PMID>
  </reference>
  <reference>
    <citation>Lundgren S, Karnevi E, Elebro J, Nodin B, Karlsson MCI, Eberhard J, Leandersson K, Jirström K. The clinical importance of tumour-infiltrating macrophages and dendritic cells in periampullary adenocarcinoma differs by morphological subtype. J Transl Med. 2017 Jul 3;15(1):152. doi: 10.1186/s12967-017-1256-y.</citation>
    <PMID>28673320</PMID>
  </reference>
  <reference>
    <citation>Lundgren S, Warfvinge CF, Elebro J, Heby M, Nodin B, Krzyzanowska A, Bjartell A, Leandersson K, Eberhard J, Jirström K. The Prognostic Impact of NK/NKT Cell Density in Periampullary Adenocarcinoma Differs by Morphological Type and Adjuvant Treatment. PLoS One. 2016 Jun 8;11(6):e0156497. doi: 10.1371/journal.pone.0156497. eCollection 2016.</citation>
    <PMID>27275582</PMID>
  </reference>
  <reference>
    <citation>Elebro J, Heby M, Warfvinge CF, Nodin B, Eberhard J, Jirström K. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. PLoS One. 2016 Apr 12;11(4):e0153533. doi: 10.1371/journal.pone.0153533. eCollection 2016.</citation>
    <PMID>27070783</PMID>
  </reference>
  <reference>
    <citation>Elebro J, Ben Dror L, Heby M, Nodin B, Jirström K, Eberhard J. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer. Acta Oncol. 2016;55(3):286-96. doi: 10.3109/0284186X.2015.1075663. Epub 2015 Sep 11.</citation>
    <PMID>26362587</PMID>
  </reference>
  <reference>
    <citation>Heby M, Elebro J, Nodin B, Jirström K, Eberhard J. Prognostic and predictive significance of podocalyxin-like protein expression in pancreatic and periampullary adenocarcinoma. BMC Clin Pathol. 2015 May 30;15:10. doi: 10.1186/s12907-015-0009-1. eCollection 2015.</citation>
    <PMID>26028992</PMID>
  </reference>
  <reference>
    <citation>Fristedt R, Elebro J, Gaber A, Jonsson L, Heby M, Yudina Y, Nodin B, Uhlén M, Eberhard J, Jirström K. Reduced expression of the polymeric immunoglobulin receptor in pancreatic and periampullary adenocarcinoma signifies tumour progression and poor prognosis. PLoS One. 2014 Nov 14;9(11):e112728. doi: 10.1371/journal.pone.0112728. eCollection 2014.</citation>
    <PMID>25397670</PMID>
  </reference>
  <reference>
    <citation>Elebro J, Heby M, Gaber A, Nodin B, Jonsson L, Fristedt R, Uhlén M, Jirström K, Eberhard J. Prognostic and treatment predictive significance of SATB1 and SATB2 expression in pancreatic and periampullary adenocarcinoma. J Transl Med. 2014 Oct 17;12:289. doi: 10.1186/s12967-014-0289-8.</citation>
    <PMID>25323550</PMID>
  </reference>
  <reference>
    <citation>Andersson G, Borgquist S, Jirström K. Hormonal factors and pancreatic cancer risk in women: The Malmö Diet and Cancer Study. Int J Cancer. 2018 Jul 1;143(1):52-62. doi: 10.1002/ijc.31302. Epub 2018 Feb 21.</citation>
    <PMID>29424426</PMID>
  </reference>
  <reference>
    <citation>Andersson G, Wennersten C, Borgquist S, Jirström K. Pancreatic cancer risk in relation to sex, lifestyle factors, and pre-diagnostic anthropometry in the Malmö Diet and Cancer Study. Biol Sex Differ. 2016 Dec 9;7:66. eCollection 2016.</citation>
    <PMID>27980714</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2018</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <keyword>adjuvant</keyword>
  <keyword>palliative</keyword>
  <keyword>prognostic</keyword>
  <keyword>predictive</keyword>
  <keyword>immune response</keyword>
  <keyword>biomarkers</keyword>
  <keyword>mutations</keyword>
  <keyword>cytokines</keyword>
  <keyword>immune cell signatures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

